AAAAAA

   
Results: 1-9 |
Results: 9
Re: CYP17 promoter polymorphism and breast cancer in Australian women under age forty years
Authors: Jernstrom, H Vesprini, D Bradlow, HL Narod, SA
Citation: H. Jernstrom et al., Re: CYP17 promoter polymorphism and breast cancer in Australian women under age forty years, J NAT CANC, 93(7), 2001, pp. 554-555
Genetic factors related to racial variation in plasma levels of insulin-like growth factor-1: Implications for premenopausal breast cancer risk
Authors: Jernstrom, H Chu, M Vesprini, D Tao, YZ Majeed, N Deal, C Pollak, M Narod, SA
Citation: H. Jernstrom et al., Genetic factors related to racial variation in plasma levels of insulin-like growth factor-1: Implications for premenopausal breast cancer risk, MOL GEN MET, 72(2), 2001, pp. 144-154
Progesterone receptor variant increases ovarian cancer risk in BRCA1 and BRCA2 mutation carriers who were never exposed to oral contraceptives
Authors: Runnebaum, IB Wang-Gohrke, S Vesprini, D Kreienberg, R Lynch, H Moslehi, R Ghadirian, P Weber, B Godwin, AK Risch, H Garber, J Lerman, C Olopade, OI Foulkes, WD Karlan, B Warner, E Rosen, B Rebbeck, T Tonin, P Dube, MP Kieback, DG Narod, SA
Citation: Ib. Runnebaum et al., Progesterone receptor variant increases ovarian cancer risk in BRCA1 and BRCA2 mutation carriers who were never exposed to oral contraceptives, PHARMACOGEN, 11(7), 2001, pp. 635-638
V89L polymorphism of type-2, 5-alpha reductase enzyme gene predicts prostate cancer presence and progression
Authors: Nam, RK Toi, A Vesprini, D Ho, M Chu, W Harvie, S Sweet, J Trachtenberg, J Jewett, MAS Narod, SA
Citation: Rk. Nam et al., V89L polymorphism of type-2, 5-alpha reductase enzyme gene predicts prostate cancer presence and progression, UROLOGY, 57(1), 2001, pp. 199-204
Modification of BRCA1- and BRCA2-associated breast cancer risk by AIB1 genotype and reproductive history
Authors: Rebbeck, TR Wang, YT Kantoff, PW Krithivas, K Neuhausen, SL Godwin, AK Daly, MB Narod, SA Brunet, JS Vesprini, D Garber, JE Lynch, HT Weber, BL Brown, M
Citation: Tr. Rebbeck et al., Modification of BRCA1- and BRCA2-associated breast cancer risk by AIB1 genotype and reproductive history, CANCER RES, 61(14), 2001, pp. 5420-5424
HPC2 variants and screen-detected prostate cancer
Authors: Vesprini, D Nam, RK Trachtenberg, J Jewett, MAS Tavtigian, SV Emami, M Ho, M Toi, A Narod, SA
Citation: D. Vesprini et al., HPC2 variants and screen-detected prostate cancer, AM J HU GEN, 68(4), 2001, pp. 912-917
Primary node negative breast cancer in BRCA1 mutation carriers has a poor outcome
Authors: Foulkes, WD Chappuis, PO Wong, N Brunet, JS Vesprini, D Rozen, F Yuan, ZQ Pollak, MN Kuperstein, G Narod, SA Begin, LR
Citation: Wd. Foulkes et al., Primary node negative breast cancer in BRCA1 mutation carriers has a poor outcome, ANN ONCOL, 11(3), 2000, pp. 307-313
Polymorphisms in GSTM1, GSTT1 and CYP1A1 and risk of pancreatic adenocarcinoma
Authors: Liu, G Ghadirian, P Vesprini, D Hamel, N Paradis, AJ Lai, G Gallinger, S Narod, SA Foulkes, WD
Citation: G. Liu et al., Polymorphisms in GSTM1, GSTT1 and CYP1A1 and risk of pancreatic adenocarcinoma, BR J CANC, 82(10), 2000, pp. 1646-1649
Intron variants of the p53 gene are associated with increased risk for ovarian cancer but not in carriers of BRCA1 or BRCA2 germline mutations
Authors: Wang-Gohrke, S Weikel, W Risch, H Vesprini, D Abrahamson, J Lerman, C Godwin, A Moslehi, R Olipade, O Brunet, JS Stickeler, E Kieback, DG Kreienberg, R Weber, B Narod, SA Runnebaum, IB
Citation: S. Wang-gohrke et al., Intron variants of the p53 gene are associated with increased risk for ovarian cancer but not in carriers of BRCA1 or BRCA2 germline mutations, BR J CANC, 81(1), 1999, pp. 179-183
Risultati: 1-9 |